Radiation plus immunotherapy before lung surgery shows promise in early trial
NCT ID NCT05500092
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding a precise, high-dose form of radiation (SBRT) to standard chemotherapy and immunotherapy (nivolumab) before surgery can improve outcomes for people with stage IIA to IIIB non-small cell lung cancer. About 17 participants were randomly assigned to receive either the standard combination or the combination plus radiation. The main goal is to see how many patients have no cancer cells left in their removed tumor tissue after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE IIA TO IIIB NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Medical Center-Albert Einstein College of Medicine
The Bronx, New York, 10461, United States
-
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
-
Washington University in St. Louis
St Louis, Missouri, 63130, United States
-
White Plains Hospital (WPH)
White Plains, New York, 10601, United States